TEL AVIV, Israel, Feb. 22, 2022 /PRNewswire/ -- SciSparc Ltd.
(NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company
focusing on the development of therapies to treat disorders of the
central nervous system (the "Company" or "SciSparc"), today
announced that it will present a company overview at the Aegis
Capital Corp. ("Aegis") Virtual Conference on February 24th at 8:30 a.m. EST. The
conference will span three days, starting on February 23rd until February 25th from 8:30
a.m. until 5 p.m. EST.
SciSparc's presentation will be available by submitting a
request to Aegis from February 23 to
February 25, 2022. The slide deck will also be made
available on SciSparc's website at
https://investor.scisparc.com/.
To access the event, please download and import the following
iCalendar (.ics) files to your calendar system: Aegis Virtual
Conference Calendar.
About SciSparc (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. Our focus is on creating and enhancing a portfolio of
technologies and assets based on cannabinoid pharmaceuticals. With
this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive
cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome,
for the treatment of obstructive sleep apnea and Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and
epilepsy.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses statements relating to its objectives,
plans, and strategies, the expected timing of trials, its product
pipeline, the research, development, and use of its platform
technologies, products and product candidates, and all statements
(other than statements of historical facts) that address
activities, events, or developments that the Company intends,
expects, projects, believes, or anticipates will or may occur in
the future . Historic results of scientific research and clinical
and preclinical trials do not guarantee that the conclusions of
future research or trials will suggest identical or even similar
conclusions. Because such statements deal with future events and
are based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F filed with the SEC on March 30,
2021, and in subsequent filings with the U.S. Securities and
Exchange Commission. Except as otherwise required by law, SciSparc
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events or
circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
View original
content:https://www.prnewswire.com/news-releases/scisparc-to-present-at-aegis-virtual-conference-301487391.html
SOURCE SciSparc Ltd.